SC-236 | CAS#170569-86-5 | COX-2 inhibitor

MedKoo Cat#: 561498 | Name: SC-236

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SC-236 is an orally active inhibitor of COX-2. SC-236 displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.

Chemical Structure

SC-236

CAS#170569-86-5

Theoretical Analysis

MedKoo Cat#: 561498

Name: SC-236

CAS#: 170569-86-5

Chemical Formula: C16H11ClF3N3O2S

Exact Mass: 401.0213

Molecular Weight: 401.78

Elemental Analysis: C, 47.83; H, 2.76; Cl, 8.82; F, 14.19; N, 10.46; O, 7.96; S, 7.98

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 225.00
10mg	USD 375.00
50mg	USD 1,010.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SC-236; SC 236; SC236;

IUPAC/Chemical Name

4-(5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

InChi Key

NSQNZEUFHPTJME-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)

SMILES Code

O=S(C1=CC=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(Cl)C=C3)C=C1)(N)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, DMF, and ethanol

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SC-236 is an inhibitor of COX-2 with an IC50 of 10 nM and approximately 18,000-fold COX-2 selectivity.

In vitro activity:

SC-236 mediates antitumor effect modulating the AP-1-signaling pathway. SC-236 inhibited 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation in JB6 cells. SC-236 inhibited anchorage-independent cell growth and AP-1-activation in 3 gastric cancer cells, independent of COX-prostaglandin synthesis. SC-236 down-regulated c-Jun-NH2-terminal kinase phosphorylation and activity. Reference: Gastroenterology. 2004 Jan;126(1):136-47. https://pubmed.ncbi.nlm.nih.gov/14699495/

In vivo activity:

SC-236 might have therapeutic potential for the prevention of liver fibrosis. In a rat model of the disease, SC-236 reduced liver fibrosis, as evident through a reduction in hepatic hydroxyproline levels, metalloproteinase-2 activity, and alpha-smooth muscle actin expression. SC-236 normalized 15d-PGJ2 levels and restored PPARgamma expression in the liver of diseased rats. Reference: FASEB J. 2005 Jul;19(9):1120-2. https://pubmed.ncbi.nlm.nih.gov/15876570/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	74.67
	DMSO	30.0	74.67
	Ethanol	30.0	74.67
	DMF	30.0	74.67
	DMSO	30.0	74.67
	Ethanol	30.0	74.67

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 401.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Yu L, Wu WK, Li ZJ, Liu QC, Li HT, Wu YC, Cho CH. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol. 2009 Jun;75(6):1364-73. doi: 10.1124/mol.108.053546. Epub 2009 Mar 5. PMID: 19264847. 2. Wong BC, Jiang XH, Lin MC, Tu SP, Cui JT, Jiang SH, Wong WM, Yuen MF, Lam SK, Kung HF. Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Gastroenterology. 2004 Jan;126(1):136-47. doi: 10.1053/j.gastro.2003.10.063. PMID: 14699495. 3. Timmons BC, Reese J, Socrate S, Ehinger N, Paria BC, Milne GL, Akins ML, Auchus RJ, McIntire D, House M, Mahendroo M. Prostaglandins are essential for cervical ripening in LPS-mediated preterm birth but not term or antiprogestin-driven preterm ripening. Endocrinology. 2014 Jan;155(1):287-98. doi: 10.1210/en.2013-1304. Epub 2013 Dec 20. PMID: 24189143; PMCID: PMC3868800. 4. Planagumà A, Clària J, Miquel R, López-Parra M, Titos E, Masferrer JL, Arroyo V, Rodés J. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005 Jul;19(9):1120-2. doi: 10.1096/fj.04-2753fje. Epub 2005 May 4. PMID: 15876570.

In vitro protocol:

In vivo protocol:

1. Timmons BC, Reese J, Socrate S, Ehinger N, Paria BC, Milne GL, Akins ML, Auchus RJ, McIntire D, House M, Mahendroo M. Prostaglandins are essential for cervical ripening in LPS-mediated preterm birth but not term or antiprogestin-driven preterm ripening. Endocrinology. 2014 Jan;155(1):287-98. doi: 10.1210/en.2013-1304. Epub 2013 Dec 20. PMID: 24189143; PMCID: PMC3868800. 2. Planagumà A, Clària J, Miquel R, López-Parra M, Titos E, Masferrer JL, Arroyo V, Rodés J. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005 Jul;19(9):1120-2. doi: 10.1096/fj.04-2753fje. Epub 2005 May 4. PMID: 15876570.

1: Kishi K, Milas L, Hunter N, Sato M. [Recent studies on anti-angiogenesis in cancer therapy]. Nihon Rinsho. 2000 Aug;58(8):1747-62. Review. Japanese. PubMed PMID: 10944947. 2: Masferrer JL, Koki A, Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 1999;889:84-6. Review. PubMed PMID: 10668485.